-Search query
-Search result
Showing 1 - 50 of 1,400 items for (author: gil & d)
EMDB-41248:
Structure of AT118-H Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor
Method: single particle / : Skiba MA, Kruse AC
EMDB-41249:
Structure of AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor and Losartan
Method: single particle / : Skiba MA, Kruse AC
PDB-8th3:
Structure of AT118-H Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor
Method: single particle / : Skiba MA, Kruse AC
PDB-8th4:
Structure of AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor and Losartan
Method: single particle / : Skiba MA, Kruse AC
EMDB-41514:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 1-1 week 0
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41515:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 1-1 at week 4
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41516:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 1-1 at week 16
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41517:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 1-1 at week 20
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41518:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 1-2 at week 0
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41519:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 2-1 at week 4
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41520:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 1-2 at week 16
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41521:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 1-2 at week 20
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41522:
Polyclonal immune complex of fab binding the H2 HA from serum of subject 1-3 at week 20
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41541:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 3-3 at week 0
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41543:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 3-3 at week 16
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41544:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 3-3 at week 20
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41545:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-1 at week 0
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41546:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-1 at week 4
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41547:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-1 at week 16
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41548:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-1 at week 20
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41549:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-2 at week 0
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41550:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-2 at week 4
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41551:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-2 at week 16
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41552:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-2 at week 20
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41553:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-3 at week 0
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41554:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-3 at week 4
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41555:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-3 at week 16
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41556:
Polyclonal immune complex of Fab binding the H2 HA from serum of subject 4-3 at week 20
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41557:
Polyclonal immune complex of Fab binding the H1 HA from serum of subject 1-1 at week 0
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41558:
Polyclonal immune complex of Fab binding the H1 HA from serum of subject 1-1 at week 4
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-41559:
Polyclonal immune complex of Fab binding the H1 HA from serum of subject 1-1 at week 16
Method: single particle / : Yang YR, Han J, Richey ST, Ward AB
EMDB-43683:
Cryo-EM structure of FLVCR2 in the inward-facing state with choline bound
Method: single particle / : Cater RJ, Mancia F
EMDB-43684:
Cryo-EM structure of FLVCR2 in the outward-facing state with choline bound
Method: single particle / : Cater RJ, Mancia F
PDB-8vzn:
Cryo-EM structure of FLVCR2 in the inward-facing state with choline bound
Method: single particle / : Cater RJ, Mancia F
PDB-8vzo:
Cryo-EM structure of FLVCR2 in the outward-facing state with choline bound
Method: single particle / : Cater RJ, Mancia F
EMDB-43658:
SARS-CoV-2 S (C.37 Lambda variant) plus S309, S2L20, and S2X303 Fabs
Method: single particle / : McCallum M, Veesler D, Seattle Structural Genomics Center for Infectious Disease (SSGCID)
EMDB-43659:
SARS-CoV-2 S NTD (C.37 Lambda variant) plus S2L20 and S2X303 Fabs, local refinement
Method: single particle / : McCallum M, Veesler D, Seattle Structural Genomics Center for Infectious Disease (SSGCID)
EMDB-43660:
SARS-CoV-2 S RBD (C.37 Lambda variant) plus S309 Fab, local refinement
Method: single particle / : McCallum M, Veesler D, Seattle Structural Genomics Center for Infectious Disease (SSGCID)
PDB-8vye:
SARS-CoV-2 S (C.37 Lambda variant) plus S309, S2L20, and S2X303 Fabs
Method: single particle / : McCallum M, Veesler D, Seattle Structural Genomics Center for Infectious Disease (SSGCID)
PDB-8vyf:
SARS-CoV-2 S NTD (C.37 Lambda variant) plus S2L20 and S2X303 Fabs, local refinement
Method: single particle / : McCallum M, Veesler D, Seattle Structural Genomics Center for Infectious Disease (SSGCID)
PDB-8vyg:
SARS-CoV-2 S RBD (C.37 Lambda variant) plus S309 Fab, local refinement
Method: single particle / : McCallum M, Veesler D, Seattle Structural Genomics Center for Infectious Disease (SSGCID)
EMDB-17329:
48S late-stage initiation complex with m6A mRNA
Method: single particle / : Guca E, Lima LHF, Boissier F, Hashem Y
EMDB-17330:
48S late-stage initiation complex with non methylated mRNA
Method: single particle / : Guca E, Lima LHF, Boissier F, Hashem Y
PDB-8p03:
48S late-stage initiation complex with m6A mRNA
Method: single particle / : Guca E, Lima LHF, Boissier F, Hashem Y
PDB-8p09:
48S late-stage initiation complex with non methylated mRNA
Method: single particle / : Guca E, Lima LHF, Boissier F, Hashem Y
EMDB-17218:
Lipidic amyloid-beta(1-40) fibril - polymorph L1
Method: helical / : Frieg B, Han M, Giller K, Dienemann C, Riedel D, Becker S, Andreas LB, Griesinger C, Schroeder GF
EMDB-17223:
Lipidic amyloid-beta(1-40) fibril - polymorph L2
Method: helical / : Frieg B, Han M, Giller K, Dienemann C, Riedel D, Becker S, Andreas LB, Griesinger C, Schroeder GF
EMDB-17234:
Lipidic amyloid-beta(1-40) fibril - polymorph L3
Method: helical / : Frieg B, Han M, Giller K, Dienemann C, Riedel D, Becker S, Andreas LB, Griesinger C, Schroeder GF
EMDB-17235:
Lipidic amyloid-beta(1-40) fibril - polymorph L2-L3
Method: helical / : Frieg B, Han M, Giller K, Dienemann C, Riedel D, Becker S, Andreas LB, Griesinger C, Schroeder GF
EMDB-17238:
Lipidic amyloid-beta(1-40) fibril - polymorph L2-L2
Method: helical / : Frieg B, Han M, Giller K, Dienemann C, Riedel D, Becker S, Andreas LB, Griesinger C, Schroeder GF
Pages: